The study titled Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma, published online March 8, 2011 in Interactive CardioVascular and Thoracic Surgery, researchers looked for studies comparing extrapleural pneumonectomy and other forms of treatment for symptom remediation. They found 14 they felt provided the best evidence to answer the question of whether or not extrapleural pneumonectomy was the superior form of mesothelioma treatment.
Of the 14 studies, 10 evaluated the role of extrapleural pneumonectomy. The average survival time of these mesothelioma,patients was 13 months with a 5.7 percent mortality rate between the time after surgery and the conclusion of hospital stay, and 9.1 percent mortality rate after 30 days.
There was a high rate of disease including atrial fibrillation, pus buildup in the space between the lung and the chest wall and irregular heartbeat in the tissue above the ventricles. The disease recurred in 73 percent of the patients after an average period of 10 months. Three months after surgery, symptoms had improved in 68 percent of the mesothelioma patients.
Two studies examined outcomes after chemotherapy. The average survival time was 13 months and symptoms improved in 50 percent of patients. The average time until the disease progressed was 7.2 months. The conditions that resulted from this treatment included an abnormally low level of white blood cells, anemia, and an abnormally low level of platelets.
Two studies examined outcomes after chemotherapy. The average survival time was 13 months and symptoms improved in 50 percent of patients. The average time until the disease progressed was 7.2 months. The conditions that resulted from this treatment included an abnormally low level of white blood cells, anemia, and an abnormally low level of platelets.
No comments:
Post a Comment